Figure 1 (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 01)
Liraglutide Injection, Solution
Product Images NDC 69097-920
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 28 technical images submitted to the FDA as part of the official labeling for Liraglutide (NDC 69097-920). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 2 (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 02)
Figure 3 (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 03)
This is a comparison chart showing the efficacy of Liraglutide Injections at 1.2 mg and 1.8 mg in comparison to Glimepiride over 52 weeks. The chart indicates statistical significance in the effectiveness of Liraglutide Injections compared to Glimepiride, with p values of 0.0014 for 1.2 mg and p<0.0001 for 1.8 mg. The data is derived from a change from baseline ANCOVA model analysis.*
Figure 4 (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 04)
The text provides data related to the comparison between liraglutide injections at 1.2 mg and 1.8 mg doses with sitagliptin at 100 mg, monitored over time up to 26 weeks using an ANCOVA model. The statistical significance of the results is indicated with a p-value (p<0.0001) highlighting the effectiveness of liraglutide injections compared to sitagliptin for the specified treatment.*
Figure 5 (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 05)
This is a clinical trial data sheet comparing the effects of Liraglutide injection versus placebo over the course of several months. The study monitored heart rate and includes patient count at various time intervals. The analysis set used is FAS (full analysis set). The efficacy of Liraglutide injection is indicated by a hazard ratio of 0.87 with a confidence interval of 95% [0.78; 0.97].*
Ifu Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 06)
This text is not readable.*
Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 10)
Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 11)
Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 12)
Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 13)
Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 14)
Not available.*
Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 15)
Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 16)
Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 17)
Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 18)
Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 19)
Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 2)
Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 20)
Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 3)
Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 4)
Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 5)
Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 6)
Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 7)
Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 8)
Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 9)
Cartonpack3pens (3penscartonpacks)
2-pens-carton-pack (Carton 2 Pens)
Prefilledcontainerlabel (Label Container)
This is a description of Liraglutide Injection, with a concentration of 18 mg/3 mL (6 mg/mL). Each prefilled pen contains 18 mg/3 mL and can deliver 30 doses of 0.6 mg, 15 doses of 1.2 mg, or 10 doses of 1.8 mg. It is intended for single patient use and should only be administered subcutaneously. The product needs to be refrigerated before the first use and not frozen. The pen should be discarded 30 days after the first use. The product is made in India by Cipla.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
